提克萨吉维玛布/奇尔加维玛布作为在患有血液性恶性瘤的患者中对SARS-CoV-2进行暴露前预防
Francesco Angotzi1, Marco Petrella1, Tamara Berno1
1Department of Medicine, Hematology and Clinical Immunology Unit, University of Padova, Padova, Italy.
Frontiers in oncology
|July 10, 2023
概括
与观察或疫苗接种相比,Tixagevimab/Cilgavimab在患有血液性恶性病的免疫功能低下患者中没有显著减少症状性SARS-CoV-2感染. 这项研究强调了在这个高风险群体中需要量身定制的预防策略.
科学领域:
- 免疫学 免疫学 免疫学
- 传染性疾病 传染性疾病
- 血液学 血液学 血液学
背景情况:
- 患有血液性恶性瘤的患者面临SARS-CoV-2感染的严重后果,并且已降低疫苗免疫性.
- 提克萨吉维马布/奇尔加维马布已获批准用于降低高危人群的SARS-CoV-2症状感染.
- 有限的数据存在Tixagevimab/Cilgavimab在血液恶性瘤患者的疗效.
研究的目的:
- 为了评估Tixagevimab/Cilgavimab暴露前预防的实际有效性.
- 为了比较接收Tixagevimab/Cilgavimab的血清阴性患者与观察或接种疫苗的血清阳性患者的SARS-CoV-2感染率.
- 评估在Omicron激增期间血液恶性瘤患者的感染预防策略.
主要方法:
- 对103名患者 (平均年龄67岁) 的前性队列研究.
- 35名患者接受了Tixagevimab/Cilgavimab;其他患者被观察或接受了第四剂疫苗.
- 随访时间为2022年3月17日至11月15日,随访时间中位数为4.24个月.
主要成果:
- 在Tixagevimab/Cilgavimab组中,SARS-CoV-2感染的3个月累计发病率为20%,在观察/疫苗组中为12%.
- 危险比 (HR) 为1.57 (95% CI: 0.65-3.56; p = 0.34),表明没有统计学上显著的差异.
- 这表明Tixagevimab/Cilgavimab在这个队列中没有提供显著的保护.
结论:
- 提克萨吉维马布/奇尔加维马布暴露前预防在患有血液恶性瘤的抗尖端血阴性患者中没有显著的益处,无法预防SARS-CoV-2感染.
- 这些发现强调了对这一脆弱人群进行个性化SARS-CoV-2预防策略的必要性.
- 可能需要进一步的研究,以优化免疫功能低下个体对COVID-19的保护.
相关概念视频
Cancer Vaccines
419
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
419
Tumor Immunotherapy
567
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
567
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Immunodeficiency Diseases
984
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
984
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Subviral Agents
44
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
44


